Compare Eli Lilly And Co (LLY) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Mesoblast Limited — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Eli Lilly And Co is far larger — about 594.3× Mesoblast Limited's market cap, and Eli Lilly And Co pays a 0.59% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Mesoblast Limited for 15 Days on average.
| LLY | MESO | |
|---|---|---|
Market Cap | $1.04T | $1.75B |
Volume | 3,064,878 | 239,027 |
Sector | Health | Health |
52-Week High | $1.28K | $20.96 |
52-Week Low | $799.57 | $13.19 |
Typical Hold Time | 93 Days | 15 Days |
Enterprise Value | $1.09T | $1.83B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
